Items Tagged ‘all’

September 26th, 2016

Rituxan Improves Survival in Young Adults with Acute Lymphoblastic Leukemia

By

Acccording to results recently published in the New England Journal of Medicine, young adults with CD20-positive, Philadelphia chromosome  (PH)-negative acute lymphoblastic leukemia (ALL), experience survival benefits with the addition of Rituxan® (rituximab) to standard chemotherapy. ALL in children is a malignant disease, or cancer of the blood, characterized by the rapid uncontrolled growth of abnormal, […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, CD20-positive, Childhood Acute Lymphoblastic Leukemia, children, Leukemia, News, Ph-negative, Philadelphia chromosome (PH)-negative acute lymphoblastic leukemia


September 6th, 2016

Inotuzumab Ozogamicin Improves Progression-Free Survival in Acute Leukemia

By

The investigative agent, inotuzumab ozogamicin, significantly improves progression-free survival and 2-year survival rates among patients with acute lymphoblastic leukemia that has stopped responding to prior therapy. These results were recently published in the New England Journal of Medicine. Acute lymphoblastic leukemia (ALL) is an aggressive form of leukemia with limited treatment options once it progresses […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, inotuzumab ozogamicin, Leukemia, lymphoblastic leukemia, News


June 23rd, 2016

Blincyto® Improves Survival in Type of Acute Lymphoblastic Leukemia

By

The immunotherapeutic agent, Blincyto (blinatumomab), improves survival compared to standard therapy among patients with B-cell precursor, Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (BCP-ALL) that has stopped responding to prior therapies. These results were presented at a presidential symposium at the 2016 annual European Hematologic Association (EHA) meeting. Acute lymphoblastic leukemia (ALL) is the most aggressive […]

View full entry

Tags: 2016, Acute Lymphoblastic Leukemia, all, BCP-ALL, blinatumomab, blincyto, EAH, Leukemia, News, TOWER trial


May 16th, 2016

Hydrocortisone Significantly Improves Neuropsychological Issues in Some Children with Leukemia

By

The use of physiologic doses of hydrocortisone appears to significantly improve neuropsychological issues caused by treatment including dexamethasone among children with acute lymphoblastic leukemia. These results were published as an early release article in the Journal of Clinical Oncology. Acute lymphoblastic leukemia (ALL) is a fast-growing form of leukemia, and is a common type of […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, children, cortisol, dexamethasone, hydrocortisone, Leukemia, News


January 19th, 2016

Blincyto® is Promising New Treatment Option for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

By

Amgen, a biotechnology company, has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, acute lymphoblastic lymphoma, all, blincyto, cd19, immunotherapy, Leukemia, News, Philadelphia chromosome positive


December 31st, 2015

Leukemia and Lymphoma Society Summarizes Major Advances in Treatment of Blood Cancers Presented at American Society of Hematology Meetings

By

For the more than one million Americans living with or in remission from a blood cancer, there is more hope than ever for new treatments and even cures—not someday, but today. Clinical findings presented at the 57th American Society of Hematology (ASH) Annual Meeting, in Orlando, December 5-8, made it increasingly clear that new discoveries […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, all, AML, ASH, blood cancer, CAR T, Chronic Lymphocytic Leukemia, CLL, fda, Leukemia, Lymphoma


July 23rd, 2015

Blincyto® in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Appears Promising

By

Biotechnology company Amgen has announced that their immunotherapy drug Blincyto® (blinatumomab) appears promising in the treatment of adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). The company announced findings from a Phase 2 trial in a recent press release. Acute lymphoblastic leukemia is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, blincyto, Leukemia, News


May 19th, 2015

Blinatumomab

By

Class: Biological Therapy Generic Name: Blinatumomab Trade Name: Blincyto® For which conditions is this drug approved? Blincyto is approved for treatment of a certain type of acute lymphoblastic leukemia (ALL): Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute ALL. What is the mechanism of action? Blincyto is a type of drug known as a monoclonal […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, B, Biological Therapy, blincyto, Drug Dictionary


February 18th, 2015

Intravenous Administration of Erwinaze® Approved by FDA

By

The U.S. Food and Drug Administration (FDA) recently approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi).  Erwinaze is utilized as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.1 Administration of Erwinaze through an intravenous infusion provides patients with hypersensitivity […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, asparaginase, asparaginase Erwinia chrysanthemi, Erwinaze, FDA approval, Leukemia, leukemia treatment, News


October 27th, 2014

CD19-Directed CAR T Cells Effective in Management of Relapsed/Refractory Acute Lymphoblastic Leukemia

By

In a study recently published in The New England Journal of Medicine, doctors have reported achieving sustained remissions in children and adults with relapsed/refractory acute lymphoblastic leukemia (ALL) using CD19-targeted chimeric antigen receptor (CAR)-modified T cells. Acute lymphoblastic lymphoma (ALL) is a fast-growing cancer of the white blood cells. Relapsed/refractory ALL in adults has a […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, CAR T, CD-19, Leukemia, News


October 10th, 2014

Amgen’s BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

By

THOUSAND OAKS, Calif., Oct. 9, 2014 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for the investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL), a rapidly progressing cancer […]

View full entry

Tags: Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia, all, amgen, blinatumomab, fda, Leukemia, News


July 21st, 2014

Dramatic Results Seen in Early Trials of Novel Lymphoma Treatment

By

A new treatment approach for B-Cell lymphoma patients developed at the National Cancer Institute (NCI) and licensed to Kite Pharmaceuticals is showing dramatic results in pilot clinical trials. The treatment, which involves extracting specific white blood cells from a patient and modifying them before infusion back into the patient, is currently involved in a phase […]

View full entry

Tags: Acute Lymphoblastic Leukemia, all, cd19, Chronic Lymphocytic Leukemia, CLL, Indolent/Low Grade Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, News, Non-Hodgkin's Lymphoma